维普中文期刊产品整合服务
12篇 您的检索式:作者名="LEIJEN S"
    题名 作者 年代 出处 被引量
1AML1/ RUNX1 increases during G(1) to S cell cycle progression in dependent of cytokine-dependent phosphorylation and induces cyclin D3 gene expression显示文摘Bernardin-Fried F Kummalue T Leijen S 2004J Biol Chem2004,279,15:1
2Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer显示文摘Leijen S Veltkamp SA Huitema AD 2013Gynecol Oncol2013,130,3:1
3AML1/RUNX1 increases during G1 to S cell cycle progression independent of cytokine-dependent phosphorylation and induces cyclin D3 gene expression显示文摘Bemardin-Fried F Kummalue T Leijen S 2004J Biol Chem2004,279,15:1
4Abrogation of the G2 check- point by inhibition of WEEI kinase results in sensitization of p53- deficient tumor cells to DNA-damaging agents显示文摘Leijen S Beijnen JH Sehellens JH 2010Curr Clin Phar- maeol2010,5,3:1
5Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitiza-tion of p53-deficient tumor cells to DNA-damaging agents 显示文摘LEIJEN S BEIJNEN J H SCHELLENS J H 2010Curr Clin Pharmacol2010,5,3:1
6Increased expression of the tight junction molecule claudin-18 A1 in both experimental colitis and ulcerative colitis显示文摘Zwiers A Fuss I J Leijen S 2008Inflamm Bowel Dis2008,14,12:1
7A phase Ⅰ and pharmacological study of MK-1775,a Weel tyrosine kinase inhibitor,in both monotherapy and in combination with gemcit-abine,cisplatin,or carboplatin in patients with advanced solid tumors显示文摘SCHELLENS J H LEIJEN S SHAPIRO G I 2009J Clin Oncol2009,27,15:1
8Phase I dose - es- calation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second - line therapy in patients with ovarian cancer 显示文摘Leijen S Vehkamp SA Huitema AD 2013Gynecol Oneol2013,130,3:1
9Phase I Dose-escalation Study of the Safety,Pharmacokinetics and Pharmacodynamics of the MEK Inhibitor RO4987655(CH4987655)in Patients with Advanced Solid Tumours显示文摘Leijen S Middleton MR Tresca P 2012Clin Cancer Res2012,18,17:1
10AML1/RUNX1 increases during G1 to S cell cycle progression independent of cytokine-dependent phosphorylation and induces cyclin D3 gene expression显示文摘Bernardin-Fried F Kummalue T Leijen S 2004J Biol Chem2004,279,15:1
11Phase I dose-esca- lation study and population pharmacokinetie analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer显示文摘Leijen S Veltkamp SA Huitema AD 2013Gynecol Oncol2013,130,3:1
12A phase and pharmacological study of MK-1775,a Wee1 tyrosine kinase inhibitor,in both monotherapy and in combination with gemcitabine,cisplatin,or carboplatin in patients with advanced solid tumors显示文摘Schellens J H Leijen S Shapiro G I 2009J Clin Oncol2009,27,15:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费